A new simple diagnostic for the identification of the major CYP2D6 genotypes by DNA sequencing analysis

International Journal of Clinical Pharmacology and Therapeutics

Volumn 42, Issue 12, 2004, Pages 719-723

  James, Heather M ^a   Coller, J K ^b   Gillis, D ^a   Bahnisch, J ^a   Sallustio, B C ^c   Somogyi, A A ^b,d  

^a INSTITUTE OF MEDICAL AND VETERINARY SCIENCE   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c QUEEN ELIZABETH HOSPITAL   (Australia)

^d ROYAL ADELAIDE HOSPITAL   (Australia)

Author keywords

Cytochrome P450 (CYP)2D6; Genotype; Pharmacogenetics; Polymorphism

Indexed keywords

CYTOCHROME P450 2D6;

ADULT; ALLELE; ARTICLE; CAUCASIAN; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA SEQUENCE; DOSE CALCULATION; DRUG METABOLISM; DRUG MONITORING; DRUG RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; EXON; GENE AMPLIFICATION; GENE DELETION; GENE FREQUENCY; GENE IDENTIFICATION; GENE MUTATION; GENOTYPE; HUMAN; HUMAN TISSUE; PHARMACOGENETICS; PHENOTYPE; POLYMERASE CHAIN REACTION; PREDICTION; RELIABILITY; RISK REDUCTION;

EID: 10344245504     PISSN: 09461965     EISSN: None     Source Type: Journal    
DOI: 10.5414/CPP42719     Document Type: Article

References (18)

1. Bathum L, Johansson I, Ingelman-Sundberg M, Høorder M, Brøsen K 1998 Ultrarapid metabolism of sparteine: frequency of alleles with duplicated CYP2D6 genes in a Danish population as determined by restriction fragment length polymorphism and long polymerase chain reaction. Pharmacogenetics 8: 119-123
2. Bertilsson L 1995 Geographical/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet 29: 192-209
3. Cesaro C, Raimundo S, Klein K, Schäffeler E, Eichelbaum M, Schwab M, Zanger UM 2003 CYP2D6 "Intermediate metabolizer" phenotype as a consequence of genetically determined alternative splicing. Chem Listy, Symposia, 97, Abstract TP41, S137
4. Chou W-H, Yan F-X, Robbins-Weilert DK, Ryder TB, Liu WW, Perbost C, Fairchild M, De Leon J, Koch WH, Wedlund PJ 2003 Comparison of two CYP2D6 genotyping methods and assessment of genotype-phenotype relationships. Clin Chem 49: 542-551
5. Evans WE, Johnson JA 2001 Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2: 9-39
6. Griese EU, Zanger UM, Brudermanns U, Gädigk A, Mikus G, Morike K, Stüven T Eichelbaum M 1998 Assessment of the predictive power of genotypes for the in vivo catalytic function of CYP2D6 in a German population. Pharmacogenetics 8: 15-26
7. Heim M, Meyer UA 1990 Genotyping of poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 336: 529-532
8. Kirchheiner J, Brosen K, Dahl ML, Gram LF, Kasper S, Roots I, Sjöqvist F, Spina E, Brockmöller J 2001 CYP2D6 and CYP2C19 genotype-based dose recommendations for antidepressants: a first step towards subpopulation-specific dosages. Acta Psychiatr Scand 104: 173-192
9. Krömer HK, Eichelbaum M 1995 "It's the genes, stupid": molecular bases and clinical consequences of genetic cytochrome P450 2D6 polymorphism. Life Sci 56: 2285-2298
10. Lundqvist E, Johansson I, Ingelman-Sundberg M 1999 Genetic mechanisms for duplication and multiplication of the human CYP2D6 gene and methods for detection of duplicated CYP2D6 genes. Gene 226 327-338
11. Marez D, Sabbagh N, Legrand M, Lo-Guidice JM, Boone P, Broly F 1995 A novel CYP2D6 allele with an abolished splice recognition site associated with the poor metabolizer phenotype. Pharmacogenetics 5: 305-311
12. Marez D, Legrand M, Sabbagh N, Lo-Guidice JM, Spire C, Lafitte J-J, Meyer UA, Broly F 1997 Polymorphism of the cytochrome P450 CYP2D6 gene in a European population: characterization of 48 mutations and 53 alleles, their frequencies and evolution. Pharmacogenetics 7: 193-202
13. Murphy GM Jr, Pollack BG, Kirshner MA, Pascoe N, Cheuk W, Mulsant BH, Reynolds CF 2001 CYP2D6 genotyping with oligonucleotide microarrays and nortriptyline concentrations in geriatric depression. Neuropsychopharmacology 25: 737-743
14. Sallustio BC, Westley IS, Morris RG 2002 Pharmacokinetics of the antianginal agent perhexiline: relationship between metabolic ratio and steady-state dose. Br J Clin Pharmacol 54 107-114
15. Stamer UM, Bayerer B, Wolf S, Hoeft A, Stuber F 2002 Rapid and reliable method for cytochrome P450 2D6 genotyping. Clin Chem 48: 1412-1417
16. Stüven T, Griese EU, Krömer HK, Eichelbaum M, Zanger UM 1996 Rapid detection of CYP2D6 null alleles by long distance- and multiplex-polymerase chain reaction. Pharmacogenetics 6: 417-421
17. Zackrisson AL, Lindblom B 2003 Identification of CYP2D6 alleles by single nucleotide polymorphism analysis using pyrosequencing. Eur J Clin Pharmacol 59: 521-526
18. Zanger UM, Raimundo S, Eichelbaum M 2004 Cytochrome P450 2D6: overview and update on pharmacology, genetics, biochemistry. Naunyn-Schmiedebergs Arch Pharmacol 369: 23-37